Professor Marco Ruggiero and his research team at the University of Florence developed the probiotic substance MAF 314 in the past several years. MAF 314 was initially seen as a potential adjunct therapy for HIV and certain cancers. More recently it has been used in ME/CFS with some success. There are anecdotal indications that MAF 314 regulates gut ecology and attacks viruses through the natural production of GcMAF. MAF 314 is known to produce an abundance of GcMAF. MAF 314 is taken at a prescribed dosage once a day.